key: cord-0823064-xbizv1qo authors: de la Guardia, C.; Rangel, G.; Villarreal, A.; Goodridge, A.; Fernandez, P. L.; Lleonart, R. title: Development of in-house, indirect ELISAs for the detection of SARS-CoV-2 spike protein-associated serology in COVID-19 patients in Panama. date: 2021-05-04 journal: nan DOI: 10.1101/2021.04.30.21256406 sha: 90629b9b8d4bcf50490ec0ba2bbd1b6d705fb34a doc_id: 823064 cord_uid: xbizv1qo COVID-19 is the name of the acute respiratory disease caused by the new coronavirus SARS-CoV-2, a close relative of those that caused the severe outbreaks of SARS and MERS several years ago. Since its first appearance in December of 2019, the COVID-19 pandemic has caused extremely high levels of mortality, morbidity, global economic breakdown, and consequent human suffering. While vaccination efforts are not extensive and rapid enough, the main tools to keep the virus under control are still keeping physical distancing, reinforce personal hygiene measures, using masks and early diagnosis of virus-infected persons, either symptomatic or not. The main diagnostic test for the confirmation of symptomatic individuals is the detection of viral RNA by reverse transcriptase-quantitative real-time PCR (RT-PCR). Additionally, serology techniques, such as ELISA are extremely useful to measure the antibodies generated in humans after virus contact, as well as the direct presence of viral antigens. In this study we aim to assemble and evaluate four ELISAs assays to measure the presence of IgG or IgM specific for the viral Spike protein in COVID-19 patients, using either the full recombinant SARS-CoV-2 Spike protein or the fragment corresponding to the receptor-binding domain. As a control, we also analyzed a group of prepandemic serum samples obtained before 2017. Strong reactivity was observed against both antigens. A few prepandemic samples displayed high OD values, suggesting the possibility of some crossreactivity. All four assays show very good repeatability, both intra-, and inter-assay; however, no clear relationship could be detected between positivity and time of sample collection for serology. Receiver operating characteristic analysis allowed the definition of cutoffs and evaluation of performance for each ELISA by estimation of the area under the curve. This performance parameter was high for all tests (AUC range: 0.98-0.995). Multiple comparisons between tests revealed no significant difference between each other (P values: 0.24-0.95). Our results show that both antigens are very effective to reveal both specific IgG and IgM antibodies, with high sensitivity (range 0.929-0.99) and specificity (range 0.933-0.977). The estimated congruence with the RT-PCR test, as estimated by Cohen Kappa, indicates a high agreement in all cases (range 0.874-0.937). This test will allow health authorities to have a new tool to estimate seroprevalence and to manage and improve the serious sanitary situation created by this virus. The new coronavirus disease 2019 (COVID-19) is a highly infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has become a world-wide pandemic with huge human and economic losses 1 . Most patients with COVID-19 develop a mild to severe respiratory illness, while others develop minimally-or asymptomatic infection 2 . Several investigations have shown that asymptomatic patients can also spread the disease 3 . Since COVID-19 was declared a global pandemic, the world has suffered more that 130 million confirmed cases and 2.8 million deaths 4 . The Americas have also been strongly affected, with more than 58 million confirmed cases and 1.4 million deceased patients (as of April 11, 2021) 5, 6 . The last available situation report for Panama, dated April 6, 2021, shows 356,373 confirmed cases and 6,131 deceased 7 . Virus specific reverse transcriptase -polymerase chain reaction (RT-PCR) has become the assay of choice to rapidly detect viral RNA sequences in acute infection of either symptomatic subjects or their contacts 8 . For symptomatic individuals, the gold standard for testing is still the RT-PCR on nasopharyngeal swab samples 9, 10 . However, RT-PCR is not devoid of important limitations, such as false-negative results 11, 12, 13, 14, 15 , variability in accuracy for different types of specimens 10 , hazardous sample collection procedure 16 and sensitivity issues 11, 16 . Besides RT-PCR, the use of serological techniques has also become an important tool for the management of the COVID-19 pandemic. In symptomatic individuals, serology testing may also help understand important points, such as the duration of virus specific antibodies 17 . For asymptomatic individuals, serology testing contributes to answer epidemiological questions, including virus exposure in general population or in particular high-risk groups, to plan public health interventions, and to monitor vaccine applications and performance 17 . In fact, we recently evaluated the performance of a rapid lateral flow immunoassay to detect IgM/IgG antibodies against SARS-CoV-2 18 . However, this type of rapid tests may present some limitations, such as not allowing quantitation of antibody titers or suboptimal sensitivity 19 . In contrast, better results may be obtained by tests based on the enzyme-linked immunosorbent assay (ELISA), which are easy and convenient to implement 20 . The humoral response of humans to the SARS-CoV-2 is apparently dominated by the production of antibodies specific for several structural proteins of the virion, mainly the Spike (S) and the Nucleocapsid (N) proteins 21 . Here we report the use of recombinant S protein, either as a full-length antigen, or just the fragment corresponding to the receptor binding domain (RBD) to assemble in-house, indirect enzyme-linked immunosorbent assays (ELISAs) for the detection of SARS-CoV-2-specific IgG and IgM antibodies. We also report the performance of the tests using a group of local COVID-19 patients and prepandemic serum samples collected before 2017. Our results confirm the usefulness of these antigens for the ELISA, opening the possibility for conducting new local studies for better knowledge and management of the disease in the country. The study population represents a sub cohort of a cross-sectional study conducted between April and December 2020 18 . Clinical serum samples were obtained from 102 hospitalized patients confirmed to be positive for SARS-CoV-2 viral infection by reverse transcriptase polymerase chain reaction (RT-PCR, done by a national reference lab) on nasopharyngeal swab testing. All participants develop moderate clinical symptoms and were treated in public hospitals located in Panama and Colon cities. For the purpose of negative control samples, 45 prepandemic serum samples were used from de-identified, bio-banked sera stored at INDICASAT-AIP. These samples correspond to research projects on tuberculosis and serosurveillance, and included 15 from patients with active pulmonary tuberculosis, 15 from patients with latent TB infections and 15 healthy individuals from blood bank. All blood samples were collected following regular procedures and centrifuged at 2000 x g for 10 min to obtain serum specimens. Serum samples were aliquoted and frozen at -80°C until testing. Prior to analysis, all serum samples were heat-inactivated at 56°C for one hour. 125/CBI/ICGES/14. All the study participants were enrolled after informed consent was given. Recombinant antigens used for ELISA were donated by Dr Florian Krammer, and consisted of 1) recombinant RBD fragment, corresponding to amino acids 319-541 plus a His tail, and 2) the full spike protein, modified as described for stabilization and multimerization (aa 1-1213) 22 . Before use, recombinant protein batches were checked for concentration and integrity by SDS-PAGE (data not shown). The ELISA assays were implemented to detect SARS-CoV-2-specific IgG and IgM antibodies specific to S and RBD antigens. Protocol was adapted from Stadlbauer et al (2020) 23 All statistical analyses were carried out using Prism v9.1.0 (GraphPad, USA) and easyROC online calculator (http://www.biosoft.hacettepe.edu.tr/easyROC/). Results of data analysis are presented as estimated statistics and their 95% confidence intervals (CI), or coefficients of variation (%CV). Normality of the optical density data was tested using Kolmogorov-Smirnov procedure. Correlation between OD data and evolution time (time elapsed between the positive RT-PCR result and serum sampling) was assessed using non parametric Spearman's rank-order correlation test. Receiver-operating characteristic (ROC) analysis was performed on ELISA OD data to calculate area under the curve (AUC) and optimal cut-off, based on procedures implemented in online calculator easyROC 24, 25 . Pairwise comparisons between the AUCs of described ELISA tests were done using the multiple comparison procedure Repeatability assessment was done by selecting two positive serum samples, including one strongly positive (OD 2) and one weakly reactive (OD 0.6), and one negative. With these samples, ELISAs were repeated, in quadruplicates, over at least five different days. Then, coefficients of variation were calculated both intra-and inter-assay using OD data. We assembled and evaluated in-house, indirect ELISAs to detect SARS-CoV-2 specific IgG or IgM antibodies in serum samples, using two recombinant viral proteins, the receptor binding domain of spike (RBD), or the full-length trimeric spike as previously reported 22 . For this study, we used serum samples from two groups, 102 COVID-19 patients and 45 prepandemic serums obtained from patients enrolled in previous studies ( Table 1) . COVID-19 patients were enrolled from May 4 to December 27, 2020 at two hospital wards including: Complejo Hospitalario Dr. Arnulfo Arias Madrid in Panama City and Hospital Manuel Amador Guerrero, Colon City. All All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 4, 2021. ; these patients had moderate symptoms and a positive RT-PCR test (median time of RT-PCR to serology, 14 days). Main clinical signs at admission were fever (76%), dysnea (72%) and cough (68%). Additionally, 73% reported to had at least one chronic disease, including hypertension (47%), type II diabetes (36%), and renal failure (11%) (data not shown). Prepandemic samples were obtained from subjects participating in tuberculosis (TB) research and surveillance programs at the Colon province, Panama. Some COVID-19 samples were negative for all ELISA tests assayed, irrespective of their time of sampling after the RT-PCR positive result (data not shown). These particular samples also tested negative previously in a rapid immunochromatography serology test measuring IgG and IgM 18 , therefore were considered non-responsive and not considered for the rest of the study. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 2) , as per the interpretation scale of Landis and Koch (1977) 27 . We attempted to evaluate if there was a relationship between the time of evolution (time after the positive RT-PCR result) and optical density data for each ELISA. Normality of the OD data sets was tested using Kolmogorov-Smirnov test, resulting in rejection of normality. Therefore, correlation between OD and time variables was assessed using non parametric Spearman's rank-order correlation test. Optical densities did not show significant correlation Table 3) . To assess the repeatability of the assays we also measure the coefficient of variation (%CV) both intra-and inter-assays, by selecting several negative, weak positive and strong positive sera and measure the dispersion of the resulting ODs at several replicates within a plate and among several plates in different days ( Table 4) . The values of CV ranged from 4% to 9%, well below the maximum tolerated of 15% for ELISA tests, indicating very good performance in terms of repeatability. In this study, we have evaluated four in-house ELISAs for the detection of antibodies against SARS-CoV-2 proteins. RBD-and full S-based ELISAs were used to detect IgM and IgG antibodies in serum samples of RT-PCR confirmed COVID-19 patients and pre-pandemic samples. As expected, most COVID-19 patients showed a strong reactivity of both types of antibodies against both the full Spike protein and the receptor binding domain. As well, most of the prepandemic serum samples remains unreactive. However, some overlap was observed in the OD values of both groups of samples, for all four assays. Some samples in the COVID-19 group remain negative, a fact already observed by some authors that suggests a lack of-or a very weak seroconversion 28, 29, 30 . In terms of the temporal behavior of the seroconversion, we did not observe a clear pattern of increase positivity in time. In fact, most of our COVID-19 group samples show very early seroconversion, while some remain negative irrespective of their time since RT-PCR All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 4, 2021. ; confirmation. This unusual trend is consistent with other reports indicating a much earlier seroconversion in COVID-19 patients 31,32,33 and a non-typical temporal pattern of responses for IgG and IgM 34 . Interestingly, some of the samples of the pre-pandemic group showed high levels of reactivity, particularly in the RBD-IgG ELISA, suggesting possible crossreactivity with pre-existing antibodies. Several authors have shown antibody crossreactivity in the immune response to several coronaviruses in human samples 28, 35, 36, 37 . Brazil, Costa Rica and Colombia 40 . Although we could not assess the contact status of our prepandemic samples with other human coronaviruses, it is conceivable that some of them may have been exposed to these endemic coronaviruses and potentially develop crossreactive antibodies. Our study presents however some limitations. The number of samples analyzed is still low. Additionally, to assess the relationship between positivity and evolution time we used the available date of RT-PCR confirmation, and this may not be a good surrogate of infection time. When available, studies should try to use the date of symptoms onset for better estimation of seroconversion time. It is also important to note that our COVID-19 cohort only include mild to moderate patients, and this fact may have influenced the strength of the immune response observed in our study. It has been shown that severity correlates with a more intense immune response and production of specific antibodies 41, 42, 43, 44, 45 . A more complete picture of the serology would have been obtained with patients from all the spectrum of the disease. Next steps should include testing of RT-PCR positive, asymptomatic subjects to characterize whether the tests are able to detect lower antibody levels likely expected in such situation. Nevertheless, our results confirm previous reports indicating the usefulness of these antigens for assays to measure seroconversion after SARS-CoV-2 infections 22, 46, 47, 48 . The ELISA tests are simple to perform and very robust once optimized. Besides, since only a very small amount of sample is required, they are very convenient. Our results are consistent with those shown by others, suggesting that these serology assays have a very good potential for studies about All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 4, 2021. ; measuring virus exposure in large groups, as well as seroconversion and seroprevalence studies in Panama. Additionally, since current vaccines being applied in Panama are based on Spike protein as immunogen, these assays may be a useful asset to study their effect and monitor the general immunological status of the population on the way to the much-needed herd immunity. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 4, 2021. ; Table 4 . Repeatability of the described ELISAs, based on calculated intra-assay and interassay coefficients of variation. (Table 2) . Controls Patients All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 4, 2021. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 4, 2021. ; https://doi.org/10.1101/2021.04.30.21256406 doi: medRxiv preprint Situation report -10. Washington: WHO The prevalence of symptoms in 24 COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries Clinical Course and Molecular Viral Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the Republic of Korea WHO declares COVID-19 a pandemic WHO Weekly epidemiological update on COVID-19 -6 PAHO COVID-19 Informe de situación de Panamá No.51 -Abril Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Laboratory diagnosis of emerging human coronavirus infectionsthe state of the art Detection of SARS-CoV-2 in Different Types of Clinical Specimens A case of imported COVID-19 diagnosed by PCR-positive lower respiratory specimen but with PCR-negative throat swabs Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Frequency of serological non-responders and false-negative RT-PCR results in SARS-CoV-2 testing: a population-based study Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT? Recent advances and perspectives of nucleic acid detection for coronavirus Algorithms for testing COVID-19 focused on use of RT-PCR and high-affinity serological testing: A consensus statement from a panel of Latin American experts Performance of a Point of Care Test for Detecting IgM and IgG Antibodies Against SARS-CoV-2 and Seroprevalence in Blood Donors and Health Care Workers in Panama. Front Med (Lausanne) Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis The ELISA, enzyme-linked immunosorbent assay Antibody responses against SARS-CoV-2 in COVID-19 patients A serological assay to detect SARS-CoV-2 seroconversion in humans SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup OptimalCutpoints: An R package for selecting optimal cutpoints in diagnostic tests An Interactive Web-tool for ROC Curve Analysis Using R Language Environment Myunghee Cho Paik (Author) The measurement of observer agreement for categorical data Serological cross-reactivity using a SARS-CoV-2 ELISA test in acute Zika virus infection, Colombia Preexisting and de novo humoral immunity to SARS-CoV-2 in humans Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation Viral Kinetics and Antibody Responses in Patients with COVID-19. medRxiv (2020) Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients Rapid generation of neutralizing antibody responses in COVID-19 patients. medRxiv Antibody responses to SARS-CoV-2 in patients with COVID-19 S protein-reactive IgG and memory B cell production after human SARS-CoV-2 infection includes broad reactivity to the S2 subunit Pediatric SARS-CoV-2: Clinical Presentation, Infectivity, and Immune Responses Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses Coronavirus infections reported by ProMED Origin and evolution of pathogenic coronaviruses Respiratory viruses and influenza-like illness: Epidemiology and outcomes in children aged 6 months to 10 years in a multi-country population sample High neutralizing antibody titer in intensive care unit patients with COVID-19. Emerg Microbes Infect SARS-CoV-2-IgG response is different in COVID-19 outpatients and asymptomatic contact persons Magnitude and Kinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity SARS-CoV-2 Antibody Responses Are Correlated to Disease Severity in COVID-19 Convalescent Individuals SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization We are very thankful to Dr. Additional support on personnel and field trips was obtained from INDICASAT-AIP. A.V., A.G., P.L. and R.L. conceived of the idea and design the experiments. C.G. and G.R. perform assay set up and antibody determinations. G.R. and R.L. analyzed the data. P.L. and R.L. wrote the paper with input from all authors.